generalized myasthenia gravis (gMG)
Apr 24, 2026
The gMG Treatment Gold Rush: Key Companies Racing Toward Breakthrough Launches by 2036
Summary Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder, with ~195,000 diagnosed patients across seven major markets in 2025, projected to reach ~250,000 by 2036. Despite recent approvals of FcRn blockers and complement inhibitors, major unmet needs remain, including unpred...
Read More...
May 16, 2025
J&J Enters gMG Arena with IMAAVY Approval, Challenging AstraZeneca, Argenx, and UCB
The FDA has approved Johnson & Johnson’s anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis (gMG). This myasthenia gravis drug will be marketed under the name IMAAVY. Although J&J isn’t the first to receive FDA approval for an FcRn-blocking antibody in this indication, the c...
Read More...
Mar 07, 2023
Incyte’s Clinical Trial for Myelofibrosis; Eisai and Bioge’s Leqembi; FDA Approves Reata Pharmaceuticals’ SKYCLARYS; Temferon Lands FDA Orphan Drug Status for Glioblastoma; Harbour BioMed Announces Results from Phase III Trial of Batoclimab; FDA Fast Track Designation to Ikena’s AHR Antagonist IK-175
Incyte Halts Phase III Clinical Trial for Myelofibrosis Incyte announced the termination of Phase III LIMBER-304 trial after the results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) revealed that the study is unlikely to meet the primary endpoint in the int...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
